Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses concerns about hair loss potentially linked to regular creatine monohydrate use and considers switching to Kre Alkalyn, which some claim doesn't cause the same issues. A user argues that Kre Alkalyn and regular creatine are functionally identical once ingested, implying no difference in hair loss effects.

A user shared their 6-month results using minoxidil 5% and finasteride 1mg daily, but still experiences significant shedding. Suggestions included seeing a dermatologist, using apple cider vinegar for dandruff, and considering oral minoxidil and dutasteride.

The user shared their 6-month hair loss progress, detailing a change in routine from using Minoxidil foam, topical Dutasteride, and topical Finasteride to using Minoxidil, oral Finasteride, derma rolling, and Keto shampoo. They seek suggestions for further improvements.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

The user is experiencing a greasy and dandruff-prone scalp from using RU58841 with glycerin and is seeking alternative carriers for seborrheic dermatitis. They are also using dutasteride 0.5mg.

Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

The user has been using minoxidil foam for 6 months but is concerned about the lack of normal hair growth. Suggestions include adding finasteride, oral minoxidil, and possibly dutasteride, along with microneedling for better results.

Creatine is unlikely to cause hair loss as it does not raise DHT levels. Hair loss is more likely due to genetics, medications, or lifestyle changes.

Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

Fibrin hydrogels, when combined with stem cells, can induce hair follicle regeneration and show potential for treating alopecia. The study demonstrated successful hair growth in mice without adverse effects.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

Adenosine is discussed as a potential treatment for hair loss, with mentions of its presence in certain shampoos and Minoxidilmax products. Users express interest in topical adenosine but are cautious about sourcing it from places like Amazon or Alibaba.

The user has been dealing with hair loss for six years using minoxidil, finasteride, and dutasteride without success. They are contemplating shaving their head due to continued hair loss and social anxiety.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A 31-year-old experienced hair regrowth using a daily regimen of 5% minoxidil spray and 1mg oral finasteride over six months, with no side effects. The user noticed slow but positive progress, especially in the temple area, and plans to continue the treatment as advised by their doctor.

The user has been using a treatment regimen for hair loss for 8 months, including topical 5% minoxidil, 2.5 mg daily minoxidil, 5 mg finasteride every other day, and vitamins. They shared progress pictures showing little change in the crown area.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user experienced significant hair regrowth and improved hair quality after six months of using oral minoxidil, finasteride, and micro-needling. They reported increased libido initially but no other side effects, and they plan to continue the treatment.

A 47-year-old male experienced significant hair regrowth over six months using 1mg oral finasteride, 5mg oral minoxidil, and 1ml 5% topical minoxidil, along with weekly derm stamping. He reported no major side effects, improved prostate health, and increased vascularity, with hair texture changes and minor nasal congestion.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Male-pattern baldness might increase UVB exposure on the scalp, potentially affecting vitamin D and skeletal health. The hypothesis is debated, with some seeing it as a minor benefit in specific contexts.